June 10, 2010 -
PRLog -- Power3 Medical (OTCBB- PWRM.OB) is a breakthrough proteomics company specializing in the identification of disease footprints in the areas of chemotherapeutic drug resistance and the early detection of breast cancer and neurological diseases.
BC-SeraPro™ is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient’s serum sample is compared to the Power3 Medical Products’ patient database.
Gen-Probe's PROGENSA(
R) PCA3 assay can help predict the outcome of initial prostate biopsies in men suspected of having prostate cancer, according to a study of the molecular urine test presented in a scientific poster last week at the 25th annual European Association of Urology (EAU) Congress in Barcelona, Spain.
PCA3 is a gene that is highly over-expressed in more than 90% of prostate cancers.
NanoViricides, Inc. (OTC BB: NNVC.OB) reports that its anti-HIV drug candidates demonstrated efficacy in the recently completed cell culture studies using two distinctly different HIV-1 isolates. The studies were performed in the laboratory of Carol Lackman-Smith at the Southern Research Institute, Frederick, Maryland.
Odyssey Marine Exploration (NASDAQCM: OMEX) Emerging Stock Report, a leading provider of sector specific independent investment research, initiated coverage on Odyssey Marine Exploration, Inc. Emerging Stock Report is currently offering a complimentary trial subscription to the investment community.
To view the Report in its entirety visit:
http://www.emergingstockreport.comLuna Innovations Inc., (NASDAQCM: LUNA) Luna Technologies, a division of Luna Innovations Incorporated, recently announced the launch of its Optical Backscatter Reflectometer™
4200 (OBR 4200), a new generation, portable, ultra-high resolution reflectometer offering advanced inspection and diagnostic capabilities to manufacturers and installers of fiber optic assemblies and short networks. The OBR 4200 offers 1000x higher resolution than the Optical Time Domain Reflectometer (OTDR) and offers an unprecedented combination of resolution and sensitivity for the first time in a portable instrument.
************************************************************
******************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!Disclaimer:
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)
